Related Experiment Video
Updated: Jan 30, 2026

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth
Published on: January 7, 2022
Small-Molecule Inhibitor of FosA Expands Fosfomycin Activity to Multidrug-Resistant Gram-Negative Pathogens
Adam D Tomich1, Erik H Klontz2,3, Daniel Deredge4
1Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Abstract:
The spread of multidrug or extensively drug-resistant Gram-negative bacteria is a serious public health issue. There are too few new antibiotics in development to combat the threat of multidrug-resistant infections, and consequently the rate of increasing antibiotic resistance is outpacing the drug development process. This fundamentally threatens our ability to treat common infectious diseases. Fosfomycin (FOM) has an established track record of safety in humans and is highly active against Escherichia coli, including multidrug-resistant strains. However, many other Gram-negative pathogens, including the "priority pathogens" Klebsiella pneumoniae and Pseudomonas aeruginosa, are inherently resistant to FOM due to the chromosomal fosA gene, which directs expression of a metal-dependent glutathione S-transferase (FosA) that metabolizes FOM. In this study, we describe the discovery and biochemical and structural characterization of ANY1 (3-bromo-6-[3-(3-bromo-2-oxo-1H-pyrazolo[1,5-a]pyrimidin-6-yl)-4-nitro-1H-pyrazol-5-yl]-1H-pyrazolo[1,5-a]pyrimidin-2-one), a small-molecule active-site inhibitor of FosA. Importantly, ANY1 potentiates FOM activity in representative Gram-negative pathogens. Collectively, our study outlines a new strategy to expand FOM activity to a broader spectrum of Gram-negative pathogens, including multidrug-resistant strains.
Insights
A new inhibitor, ANY1, targets the FosA enzyme, which confers resistance to the antibiotic fosfomycin (FOM) in Gram-negative bacteria. This discovery offers a strategy to restore FOM
Area of Science:
- Microbiology
- Drug Discovery
- Biochemistry
Background:
- Multidrug-resistant Gram-negative bacteria pose a significant public health threat.
- Existing antibiotic development pipelines are insufficient to combat rising resistance.
- Fosfomycin (FOM) is effective against some Gram-negative bacteria but not others, like Klebsiella pneumoniae and Pseudomonas aeruginosa, due to the FosA enzyme.
Purpose of the Study:
- To discover and characterize a small-molecule inhibitor of the FosA enzyme.
- To develop a strategy to expand the activity spectrum of fosfomycin.
Main Methods:
- Discovery and characterization of ANY1, a small-molecule inhibitor of FosA.
- Biochemical and structural analysis of ANY1's interaction with FosA.
- Testing ANY1's ability to potentiate FOM activity in Gram-negative pathogens.
Main Results:
- ANY1 was identified as an active-site inhibitor of the FosA enzyme.
- ANY1 was biochemically and structurally characterized.
- ANY1 demonstrated potentiation of FOM activity in Gram-negative pathogens, including resistant strains.
Conclusions:
- ANY1 represents a novel strategy to overcome FosA-mediated fosfomycin resistance.
- This approach can broaden the utility of fosfomycin against a wider range of Gram-negative pathogens.
- The findings offer a new therapeutic avenue for treating multidrug-resistant infections.
More Related Videos
09:29In Vivo Investigation of Antimicrobial Blue Light Therapy for Multidrug-resistant Acinetobacter baumannii Burn Infections Using Bioluminescence Imaging
Published on: April 28, 2017
23:06The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
Published on: August 11, 2008
Related Concept Videos
Negative Regulator Molecules
Gram-negative Bacterial Protein Secretion Systems
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Positive, Negative, and Zero Work
Molecules and Compounds
Resistivity